spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Graft vs. Host Disease 

 HSMN NewsFeed - 8 Mar 2017
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Sep 2010
Athersys Receives Orphan Drug Designation for MultiStem in Graft vs. Host Disease
Regenerative Medicine FDA
 HSMN NewsFeed - 24 Feb 2010
New Study Demonstrates Effectiveness of Prochymal as a Rescue Therapy for Pediatric Patients with Severe Graft vs. Host Disease
Biopharmaceuticals
 HSMN NewsFeed - 15 Jan 2009
Osiris Receives FDA Clearance to Broaden Prochymal Expanded Access Program
Regenerative Medicine FDA
 HSMN NewsFeed - 5 Dec 2008
Osiris Receives Approval for Prochymal Expanded Access Program in Canada
Biopharmaceuticals Regenerative Medicine Regulatory
 HSMN NewsFeed - 8 May 2008
Osiris Receives Approval for Use of Prochymal(TM) Under FDA Expanded Access Treatment Program
Regenerative Medicine FDA
 HSMN NewsFeed - 10 Dec 2007
Osiris Therapeutics Reports Positive Results for Prochymal(TM) as a Rescue Agent in Pediatric Patients with End-Stage Graft vs. Host Disease
Regenerative Medicine
 HSMN NewsFeed - 9 Dec 2006
Osiris Therapeutics Provides Update on Phase II Trial Evaluating PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
Biopharmaceuticals
 HSMN NewsFeed - 9 Nov 2006
Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL(TM) for the Treatment of Acute Graft vs. Host Disease
Biopharmaceuticals Regenerative Medicine
 HSMN NewsFeed - 19 Oct 2006
Osiris Therapeutics Reports Positive Phase II Results Using PROCHYMAL(TM) in Treatment-Resistant Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 17 Oct 2006
Osiris is Granted European Manufacturing Certification for PROCHYMAL(TM)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Oct 2006
Osiris Therapeutics Receives Approval from Health Canada to Conduct Phase III Clinical Trial for Lead Stem Cell Drug
Biopharmaceuticals Regenerative Medicine Regulatory
Return to NewsFeed  

 Additional items found! 7

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 7 additional stories matching:
Graft vs. Host Disease
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.